Advertisement

Journal of Neuro-Oncology

, Volume 23, Issue 2, pp 135–147 | Cite as

Spinal cord compression in prostate cancer

  • Jennifer L. Osborn
  • Robert H. Getzenberg
  • Donald L. Trump
Article

Abstract

Approximately 200,000 men will be diagnosed with prostate cancer in 1994. While localized disease is potentially curable with surgery or radiation therapy, metastatic disease is incurable. The most frequent site of metastasis is bone. Spinal cord compression occurs in approximately 7% of men with prostate cancer. Back pain often heralds the diagnosis of spinal cord compression. In prostate cancer patients with back pain or signs of myelopathy or radiculopathy, plain radiographs of the spine and magnetic resonance imaging should be performed. Early diagnosis is of utmost importance. The neurologic status prior to treatment is the major determinant influencing outcome. Following diagnosis, corticosteroid therapy should begin immediately. Hormonal therapy should be instituted in those patients who have not previously undergone hormonal manipulation. The standard approach to definitive therapy is radiation. Surgical decompression plays a role in patients with severe myelopathy, spinal instability, and in those patients whose neurologic status deteriorates during or after radiation therapy.

Key words

prostate cancer metastasis spinal cord compression radiotherapy surgery 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    American Cancer Society: Cancer Facts & Figures — 1994. Atlanta, American Cancer Society, 1994Google Scholar
  2. 2.
    Constans JP, de Devitiis E, Donzelli R, Spaziante R, Meder JF, Haye C: Spinal metastasis with neurological manifestations. J Neurosurg 59: 111–118, 1983PubMedGoogle Scholar
  3. 3.
    Sorensen PS, Borgesen SE, Rohde K, Rasmusson B, Bach F, Boge-Rasmussen T, Stjernholm P, Larsen BH, Agerlin N, Gjerris F: Metastatic epidural spinal cord compression: Results of treatment and survival. Cancer 65: 1502–1508, 1990PubMedGoogle Scholar
  4. 4.
    Gilbert RW, Kim JH, Posner JB: Epidural spinal cord compression from metastatic tumor: Diagnosis and treatment. Ann Neurol 3: 40–51, 1978Google Scholar
  5. 5.
    Greenberg HS, Kim JH, Posner JB: Epidural spinal cord compression from metastatic tumor: Results from a new protocol. Ann Neurol 8: 361–366, 1980PubMedGoogle Scholar
  6. 6.
    Kuban DA, El-Mahdi AM, Sigfred SV, Schellhammer PF, Babb TJ: Characteristics of spinal cord compression in adenocarcinoma of prostate. Urology 28: 364–369, 1986PubMedGoogle Scholar
  7. 7.
    Smith EM, Hampel N, Ruff RL, Bodner DR, Resnick MI: Spinal cord compression secondary to prostate carcinoma: Treatment and prognosis. J Urol 149: 330–333, 1993PubMedGoogle Scholar
  8. 8.
    Jacobs SC: Spread of prostatic cancer to bone. Urology 21: 337–344, 1983PubMedGoogle Scholar
  9. 9.
    Galasko CSB: The anatomy and pathways of skeletal metastases. In: Weiss L, Gilbert HA (eds) Bone Metastasis. Boston: G.K. Hall, 1981, pp 49–63Google Scholar
  10. 10.
    Mundy GR, Spiro TP: The mechanism of bone metastasis and bone destruction by tumor cells. In: Weiss L, Gilbert HA (eds) Bone Metastasis, Boston: G.K. Hall, p 64Google Scholar
  11. 11.
    Chackal-Roy M, Neimeyer C, Moore M, Zetter BR: Stimulation of human prostatic carcinoma cell growth by factors present in human bone marrow. J Clin Invest 84: 43–50, 1989PubMedGoogle Scholar
  12. 12.
    Haq M, Goltzman D, Tremblay G, Brodt P: Rat prostate adenocarcinoma cells disseminate to bone and adhere preferentially to bone marrow-derived endothelial cells. Cancer Research 52: 4613–4619, 1992PubMedGoogle Scholar
  13. 13.
    Auerbach R, Lu WC, Pardon E, Gumkowsky F, Kaminska G: Specificity of adhesion between murine tumor cells and capillary endothelium: anin vitro correlate of preferential metastasisin vivo. Cancer Research 47: 1492–1496, 1987PubMedGoogle Scholar
  14. 14.
    Kincade PW, Lee G, Pietrangeli CE, Hayashi SI, Gimble M: Cells and molecules that regulate B lymphopoiesis in bone marrow. Annual Rev Immunol 7: 111–143, 1989Google Scholar
  15. 15.
    Wu H-C, Hsieh J-T, Gleave ME, Brown NM, Pathak S, Chung LWK: Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 57: 406–412, 1994PubMedGoogle Scholar
  16. 16.
    Chung LWK: Implications of stromal-epithelial interaction in human prostate cancer growth, progession and differentiation. Seminars in cancer biology, 4: 138–192, 1993Google Scholar
  17. 17.
    McKeehan WL, Adams PS: Heparin-binding growth factor prostatropin attentuates inhibition of rat prostate tumors epithelial cell growth by transforming growth factor type beta.In vitro Cell Dev Biol 24: 243–246, 1988PubMedGoogle Scholar
  18. 18.
    Perkel VS, Subburanman M, Baylind DJ, Linkhart TA: An inhibitory insulin-like growth factor binding protein (IN-IGFBP) from human prostate cell conditioned medium reveals N-terminal sequence identity with bone-derived IN-IGFBP. J Clin Endoc and Metab 71: 533–535, 1990Google Scholar
  19. 19.
    Gleave ME, Hsich JT, von Eschenbach AC, Chung LWK: Prostate and bone fibroblasts induce human prostate cancer growthin vivo: implications for bidirectional tumor-stromal cell interactions in prostate carcinoma growth and metastasis. J Urol 147: 1151–1159, 1992PubMedGoogle Scholar
  20. 20.
    Sullivan LM, Quigley JP: An anticatalytic monoclonal antibody to avian plasminogen activator: its effect on the behavior of RSV-transformed chick fibroblasts. Cell 45: 905–915, 1986PubMedGoogle Scholar
  21. 21.
    Kirchheimer JC, Wojta J, Christ G, Binder BR: Proliferation of a human epidermal tumor cell line stimulated by urokinase. FASEB J 1: 125–128, 1987PubMedGoogle Scholar
  22. 22.
    Goltzman D, Bolivar I, Moroz LA, Rabbani SA: Urokinase and the mechanism of osteoblastic metastases by prostate cancer. Fibrinolysis 6: 63–69, 1992Google Scholar
  23. 23.
    Kirchheminer JC, Koller A, Binder BR: Isolation and characterization of plasminogen activators from hyperplastic and malignant prostate tissue. Biochem Biophys Acta 797: 256–265, 1984PubMedGoogle Scholar
  24. 24.
    Kirchheimer JC, Pfluger H, Ritschl P, Hichert G, Binder BR: Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumors. Invasion metastasis 5: 344–355, 1985PubMedGoogle Scholar
  25. 25.
    Gaylis FD, Keer HN, Wilson MJ, Kwaan HC, Sinha AA, Kozlowski JM: Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype. J Urology 142: 193–198, 1989Google Scholar
  26. 26.
    Sadasivan R, Van Veldhuizen P, Horrat B, Dwyer T, Kimura M, Austenfeld M, Garcia F: Deletions of the gene for plasminogen activators uPA and tPA in human prostate carcinoma. Cancer Research 34: 194, 1993Google Scholar
  27. 27.
    Hollas W, Hoosein N, Chung LWK, Mazar A, Henkin J, Kariko K, Barnathan ES, Boyd D: Expression of urokinase and its receptor in invasive an non-invasive prostate cancer cell lines. Thrombosis and Haemostasis 68: 662–666, 1992PubMedGoogle Scholar
  28. 28.
    Hoosein NM, Boyd DD, Hollas WJ, Mazar A, Henkin J, Chung LWK: Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines. Cancer Communications 3: 255–264, 1991PubMedGoogle Scholar
  29. 29.
    Achbarou A, Kaiser S, Tremblay G, Ste-Marie L-G, Brodt P, Goltzman D, Rabbani SA: Urokinase overproduction results in increased skeletal metastases by prostate cancer cellsin vivo. Cancer Research 54: 2372–2377, 1994PubMedGoogle Scholar
  30. 30.
    Getzenberg RH, Coffey DS: Tissue specificity of the hormonal response in sex accessory tissues is associated with nuclear matrix protein patterns. Mol Endo 4: 1336–1342, 1990Google Scholar
  31. 31.
    Getzenberg RH: The nuclear matrix and the regulation of gene expression: tissue specificity. J Cell Biochem 55: 22–31, 1994PubMedGoogle Scholar
  32. 32.
    Getzenberg RH, Pienta KJ, Huang EYW, Coffey DS: Identification of nuclear matrix proteins in the cancer and normal rat prostate. Cancer Res 51: 6514–6520, 1991PubMedGoogle Scholar
  33. 33.
    Partin AW, Getzenberg RH, CarMichael MJ, Vindivich D, Yoo J, Epstein JI, Coffey DS: Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostate cancer. Cancer Res 53: 744–746, 1993PubMedGoogle Scholar
  34. 34.
    Stark RJ, Henson RA, Evans SJW: Spinal metastasis: a retrospective survey from a general hospital. Brain 105: 189–213, 1982PubMedGoogle Scholar
  35. 35.
    Byrne TN: Spinal cord compression from epidural metastasis. New Eng J Med 327: 614–619, 1992PubMedGoogle Scholar
  36. 36.
    Shoskes DA, Perrin RG: The role of surgical management for symptomatic spinal cord compression in patients with metastatic prostate cancer. J Urol 142: 337–339, 1989PubMedGoogle Scholar
  37. 37.
    Zelefsky MJ, Scher HI, Krol G, Portenoy RK, Leibel SA, Fuks ZY: Spinal epidural tumor in patients with prostate cancer. Cancer 70: 2319–2325, 1992PubMedGoogle Scholar
  38. 38.
    Rosenthal MA, Rosen D, Raghavan D, Leicester J, Duval P, Bessor M, Pearson B: Spinal cord compression in prostate cancer: A 10 year experience. B J Urol 69: 530–533, 1992Google Scholar
  39. 39.
    Flynn DF, Shipley WU: Management of spinal cord compression secondary to metastatic prostate carcinoma. Urol Clin N Amer 18: 145–152, 1989Google Scholar
  40. 40.
    Harrington KD: Anterior cord decompression and spinal stabilization for patients with metastatic lesions of the spine. J Neurosurg 61: 107–117, 1984PubMedGoogle Scholar
  41. 41.
    Rodichok LD, Harper GR, Ruckdeschel JC, Price A, Roberson G, Barron KD, Horton J: Early diagnosis of spinal epidural metastases. Am J Med 70: 1181–1188, 1981PubMedGoogle Scholar
  42. 42.
    Portenoy RK, Galer BS, Salamon O, Freilich M, Finkel JE, Milstein D, Thaler HT, Berger M, Lipton RB: Identification of epidural neoplasm: radiography and bone scintigraphy in the symptomatic and asymptomatic spine. Cancer 64: 2207–2213, 1989PubMedGoogle Scholar
  43. 43.
    Graus F, Krol G, Foley K: Early diagnosis of spinal cord epidural metastasis: Correlation of clinical and radiologic findings. Proc Am Soc Clin Oncol 4: 269, 1985 (abstract)Google Scholar
  44. 44.
    Carmody RF, Yang PJ, Seeley GW, Seeger JF, Unger EC, Johnson JE: Spinal cord compression due to metastatic disease: Diagnosis with MR imaging versus myelography. Radiology 173: 225–229, 1989PubMedGoogle Scholar
  45. 45.
    Bonner JA, Lichter AS: A caution about the use of MRI to diagnose spinal cord compression. New Eng J Med 332: 556–557, 1990Google Scholar
  46. 46.
    Ushio Y, Posner R, Posner JB, Shapiro WR: Experimental spinal cord compression by epidural neoplasms. Neurology 27: 422–429, 1977PubMedGoogle Scholar
  47. 47.
    Ushio Y, Posner R, Kim JH, Shapiro WR, Posner JB: Treatment of experimental spinal cord compression caused by extradural neoplasms. J Neurosurg 47: 380–390, 1977PubMedGoogle Scholar
  48. 48.
    Vecht CJ, Haaxma-Reiche H, van Putten WLJ, de Visser M, Vries EP, Twijnstra A: Initial bolus of conventional versus high dose dexamethasone in spinal cord compression. Neurology 39: 1255–1257, 1989PubMedGoogle Scholar
  49. 49.
    Iacovou JW, Marks JC, Abrams PH, Gingell JC, Ball AJ: Cord compression and carcinoma of the prostate: Is laminectomy justified? B J Urol 57: 733–736, 1985Google Scholar
  50. 50.
    Young RF, Post EM, King GA: Treatment of spinal epidural metastasis: Randomized prospective comparison of laminectomy and radiotherapy. J Neurosurg 53: 741–748, 1980PubMedGoogle Scholar
  51. 51.
    Tang SG, Byfield JE, Sharp TR, Utley JF, Quinol L, Seagren SL: Prognostic factors in the management of metastatic epidural spinal cord compression. J Neuro-oncol 1: 21–28, 1983Google Scholar
  52. 52.
    Kaminski HJ, Diwan VG, Ruff RL: Second occurrence of spinal epidural metastasis. Neurology 41: 744–746, 1991PubMedGoogle Scholar
  53. 53.
    Sundaresan N, Galicich JH, Lane JM, Bains MS, McCormack P: Treatment of neoplastic epidural cord compression by vertebral body resection and stabilization. J Neurosurg 63: 676–684, 1985PubMedGoogle Scholar
  54. 54.
    Siegal T, Siegal T, Robin G, Lubetski-Korn I, Fuks Z: Anterior decompression of the spine for metastatic epidural cord compression: A promising avenue of therapy. Ann Neurol 11: 28–34, 1982PubMedGoogle Scholar
  55. 55.
    Siegal T, Tiqva P, Siegal T: Vertebral body resection for epidural compression by malignant tumors: Results of forty-seven consecutive operative procedures. J Bone and Joint Surg 61-A: 375–382, 1985Google Scholar
  56. 56.
    Sundaresan N, Digiacinto GV, Hughes JEO, Cafferty M, Vallejo A: Treatment of neoplastic spinal cord compression: Results of a prospective study. Neurosurgery 29: 645–650, 1991PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1995

Authors and Affiliations

  • Jennifer L. Osborn
    • 1
  • Robert H. Getzenberg
    • 2
    • 3
  • Donald L. Trump
    • 1
    • 3
  1. 1.Department of Medicine, Division of Medical OncologyUniversity of Pittsburgh School of MedicinePittsburgh
  2. 2.Department of PathologyUniversity of Pittsburgh School of MedicinePittsburgh
  3. 3.Prostate and Urologic Cancer CenterPittsburgh Cancer InstitutePittsburghUSA

Personalised recommendations